Stock Price Targets and Analyst Ratings

Stay on top of the latest U.S. and international stock analyst recommendations with our up-to-date list of stock price targets and analyst ratings. This page tracks newly issued analyst ratings, price targets, upgrades, downgrades, and other broker actions to help you see how Wall Street analysts view the companies you follow. Use these ratings to compare sentiment, spot shifts in outlook, and make more informed investment decisions.

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
A Agilent Technologies	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$135.03 -0.7%		Peer Perform
AAVMY ABN AMRO Bank	Upgraded by	ABN Amro Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$40.09 +1.2%		Neutral ➝ Buy
ABG Asbury Automotive Group	Reiterated by	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Lick Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$189.95 +1.8%	$242.00	Overweight
ABVX Abivax	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Julian Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$150.00	Buy
ABVX Abivax	Upgraded by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$110.00 ➝ $90.00	Underperform ➝ Neutral
ABVX Abivax	Target Raised by	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason N. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$131.00 ➝ $187.00	Market Outperform
ABVX Abivax	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$72.50 -44.1%		Outperform
ABVX Abivax	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$160.00 ➝ $90.00	Buy ➝ Hold
ABVX Abivax	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$145.00 ➝ $132.00	Overweight
ABVX Abivax	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$140.00 ➝ $135.00	Buy
One page of the SpaceX S-1 will move this stock overnight (Ad) When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown. See the stock the S-1 revealed >>
ACN Accenture	Target Lowered by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$186.27 -5.2%	$210.00 ➝ $199.00	Hold
ACRE Ares Commercial Real Estate	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.03 +1.9%	$5.00 ➝ $5.50	Neutral
ACRS Aclaris Therapeutics	Initiated by	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$4.63 +6.7%	$13.00	Outperform
AESI Atlas Energy Solutions	Upgraded by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Rollyson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.02 +5.3%	$25.00	Market Perform ➝ Outperform
AKTS Aktis Oncology	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$20.26 +4.0%	$33.00 ➝ $35.00	Buy
ALB Albemarle	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$172.12 +0.6%	$153.00 ➝ $192.00	Hold
ALGT Allegiant Travel	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Didora Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$87.67 -1.7%	$90.00 ➝ $100.00	Neutral
ALT Altimmune	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2.90 -3.7%		Market Outperform
APN APN Resources	Target Raised by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 272	GBX 306 ➝ GBX 335	Buy
ARMK Aramark	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Bisbee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$54.06 -0.6%	$59.00 ➝ $62.00	Buy
ARXS Arxis	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Godyn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.84 -0.6%	$42.00 ➝ $50.00	Buy
ASST Strive	Initiated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Palmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.12 -6.3%	$32.00	Buy
ASTH Astrana Health	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$36.91 -2.3%	$50.00	Buy
AZN AstraZeneca	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		£134.34	£115 ➝ £115	Sell
BBY Best Buy	Target Raised by	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$72.93 -2.7%	$68.00 ➝ $77.00	Neutral
BLCO Bausch + Lomb	Target Set by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$14.97 -2.7%	$19.00	Buy
BLND British Land	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 395	GBX 305 ➝ GBX 305	Underperform
BLND British Land	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 395	GBX 531 ➝ GBX 534	Buy
BSIF Bluefield Solar Income Fund	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 91.40		Hold
BTSG BrightSpring Health Services	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$59.34 -1.1%	$62.00 ➝ $71.00	Overweight
BWA BorgWarner	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Langan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$74.18 +4.4%	$68.00 ➝ $83.00	Overweight
BXMT Blackstone Mortgage Trust	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.30 +2.0%	$20.00 ➝ $21.00	Neutral ➝ Buy
BXP BXP	Reiterated by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$61.12 +3.4%	$68.00	Outperform
CAG Conagra Brands	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bryan Adams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$12.86 -1.9%	$16.00 ➝ $13.00	Neutral
CAT Caterpillar	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$910.03 +5.2%	$900.00	Neutral
CELC Celcuity	Target Set by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Berens Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$91.42 -25.7%	$155.00
CER Cerillion	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 1,350	GBX 1,575 ➝ GBX 1,575	Hold
CGEMY Cap Gemini	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$23.44 -5.4%		Buy
CHWY Chewy	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Doug Anmuth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$21.48 -3.6%	$40.00 ➝ $35.00	Overweight
CIEN Ciena	Target Raised by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dave Kang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$628.98 +10.4%	$283.00 ➝ $531.00	Neutral
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
CORT Corcept Therapeutics	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$71.20 +1.1%	$75.00 ➝ $95.00	Buy
CPB Campbell's	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$20.99 -0.4%	$20.00 ➝ $19.00	Sell
CRDO Credo Technology Group	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Cardoso Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$230.00 ➝ $250.00	Overweight
CRDO Credo Technology Group	Target Raised by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean O'Loughlin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$240.00 ➝ $260.00	Buy
CRDO Credo Technology Group	Target Raised by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Genovese Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$175.00 ➝ $215.00	Neutral
CRDO Credo Technology Group	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vivek Arya Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$210.00 ➝ $252.00	Buy
CRDO Credo Technology Group	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Schneider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$250.00	Buy
CRDO Credo Technology Group	Target Raised by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Rakesh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$260.00 ➝ $290.00	Outperform
CRDO Credo Technology Group	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Rolland Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$200.00 ➝ $235.00	Positive
CRDO Credo Technology Group	Target Raised by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Blayne Curtis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$225.00 ➝ $270.00	Buy
CRDO Credo Technology Group	Target Raised by	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suji Desilva Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.00 +1.3%	$200.00 ➝ $300.00	Buy
CRWV CoreWeave	Initiated by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stefan Slowinski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$119.27 -4.4%	$192.00	Outperform
CZR Caesars Entertainment	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trey Bowers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.22 +0.2%	$26.00 ➝ $31.00	Equal Weight
DELL Dell Technologies	Target Raised by	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$433.72 -6.9%	$170.00 ➝ $465.00	Outperform
DG Dollar General	Target Set by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scot Ciccarelli Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$106.78 -2.9%	$114.00
DOCS Dr. Martens	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 72.30	GBX 100 ➝ GBX 100	Sector Perform
DRTS Alpha Tau Medical	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yi Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.93 -7.6%	$15.00	Buy
DRX Drax Group	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 792.45	GBX 1,120 ➝ GBX 1,120	Buy
DUK Duke Energy	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$120.88 +0.8%	$139.00	Buy
DVN Devon Energy	Target Lowered by	Capital One Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$46.24 -0.2%	$63.00 ➝ $61.00	Overweight
EBS Emergent Biosolutions	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$8.19 -3.6%		Buy
EBS Emergent Biosolutions	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$8.19 -3.6%		Buy
ED Consolidated Edison	Reiterated by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Crowdell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$103.75 +0.1%	$105.00	Outperform ➝ Neutral
EDV Endeavour Mining	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 4,417	GBX 6,000 ➝ GBX 6,000	Outperform
EIKN Eikon Therapeutics	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$9.60 -11.0%		Overweight
ELM Elementis	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 151.80	GBX 210 ➝ GBX 210	Buy
ELVN Enliven Therapeutics	Target Raised by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.52 -5.3%	$45.00 ➝ $62.00	Outperform
ENHA Enhanced Group	Initiated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Susan Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2.84 -0.5%	$6.00	Buy
ENT Entain	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 554.60	GBX 1,028 ➝ GBX 1,028	Buy
EW Edwards Lifesciences	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$87.59 -0.6%	$97.00 ➝ $104.00	Buy
EWTX Edgewise Therapeutics	Target Lowered by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.25 -7.5%	$50.00 ➝ $48.00	Outperform
EWTX Edgewise Therapeutics	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lander Egaña Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.25 -7.5%	$42.00 ➝ $45.00	Buy
EXP Eagle Materials	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adrian Huerta Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$219.05 -0.9%	$225.00	Underweight ➝ Neutral
EXPO Exponent	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Chan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$58.39 -3.3%	$75.00	Neutral
EZJ easyJet	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 437.90	GBX 340 ➝ GBX 340	Sell
FCX Freeport-McMoRan	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nick Cash Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$71.64 +6.9%	$68.00 ➝ $75.00	Buy
FDX FedEx	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Hoexter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$328.76 -2.9%	$440.00 ➝ $376.00	Buy
FDX FedEx	Target Lowered by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$328.76 -2.9%	$335.00 ➝ $269.76	Neutral
FDX FedEx	Target Lowered by	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$328.76 -2.9%	$375.00 ➝ $344.00	Neutral
FDX FedEx	Target Set by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lucas Servera Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$328.76 -2.9%	$155.00
FLY Firefly Aerospace	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sheila Kahyaoglu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$43.37 -2.0%		Buy
FRSH Freshworks	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$10.16 -4.9%		Market Outperform
FULC Fulcrum Therapeutics	Target Set by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$3.14 -51.1%	$4.00
FULC Fulcrum Therapeutics	Downgraded by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Overweight ➝ Neutral
FULC Fulcrum Therapeutics	Reiterated by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$4.00	Buy ➝ Hold
FULC Fulcrum Therapeutics	Downgraded by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Buy ➝ Neutral
FULC Fulcrum Therapeutics	Reiterated by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Condulis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Buy ➝ Hold
FULC Fulcrum Therapeutics	Reiterated by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$4.00	Outperform ➝ Market Perform
FVR FrontView REIT	Reiterated by	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Erdner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.18 +1.4%	$19.00	Buy
GH Guardant Health	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$130.17 +0.8%	$150.00	Outperform
Musk is burning $2.5 billion a quarter on AI. One company holds the key. (Ad) SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost. Read the S-1 breakdown and get the company name free
GH Guardant Health	Upgraded by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$130.17 +0.8%	$160.00	In-Line ➝ Outperform
GIS General Mills	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Yaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$33.07 -1.7%	$36.00	Neutral
GIS General Mills	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$33.07 -1.7%	$35.00 ➝ $30.00	Sell
GNRC Generac	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean Milligan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$284.25 +5.6%		Buy
GNSS Genasys	Target Raised by	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Woo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2.03 -3.8%	$5.50 ➝ $6.00	Buy
GOOG Alphabet	Reiterated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$358.39 -3.8%	$435.00	Overweight
GOOGL Alphabet	Reiterated by	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Rossington Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$361.85 -3.9%	$435.00 ➝ $420.00	Buy
GRAL GRAIL	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$59.90 -7.0%		Peer Perform
GWRE Guidewire Software	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allan Verkhovski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$162.51 -5.2%	$200.00	Buy
GWRE Guidewire Software	Reiterated by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Heckmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$162.51 -5.2%	$246.00	Buy
HNHPF Hon Hai Precision Industry Co., Ltd. Sponsored GDR	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$19.64 +2.2%	$22.00	Overweight
HPE Hewlett Packard Enterprise	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Fish Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$23.00 ➝ $63.00	Neutral
HPE Hewlett Packard Enterprise	Reiterated by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Niknam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$31.00 ➝ $69.00	Buy
HPE Hewlett Packard Enterprise	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asiya Merchant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$39.00 ➝ $70.00	Buy
HPE Hewlett Packard Enterprise	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Long Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$28.00 ➝ $67.00	Overweight
HPE Hewlett Packard Enterprise	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Meta Marshall Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$33.00 ➝ $71.00	Equal Weight
HPE Hewlett Packard Enterprise	Target Raised by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark C. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$35.00 ➝ $62.00	Market Perform
HPE Hewlett Packard Enterprise	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Vogt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$25.00 ➝ $65.00	Neutral
HPE Hewlett Packard Enterprise	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Aaron Rakers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$26.00 ➝ $67.00	Equal Weight
HPE Hewlett Packard Enterprise	Target Raised by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Simon Leopold Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$29.00 ➝ $74.00	Outperform
HPE Hewlett Packard Enterprise	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mehdi Hosseini Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$21.00 ➝ $65.00	Neutral
HPE Hewlett Packard Enterprise	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samik Chatterjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$37.00 ➝ $68.00	Overweight
HPE Hewlett Packard Enterprise	Upgraded by	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ananda Baruah Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$23.00 ➝ $75.00	Hold ➝ Buy
HPE Hewlett Packard Enterprise	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wamsi Mohan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.05 +19.3%	$38.00 ➝ $80.00	Buy
HPQ HP	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ng Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$27.27 -7.1%	$16.00 ➝ $19.00	Sell
HST Host Hotels & Resorts	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robin Farley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$23.65 +2.0%	$20.00 ➝ $23.00	Neutral
IAC IAC	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Kurnos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.86 -5.6%		Buy
IAUX i-80 Gold	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1.63 +1.6%	$2.60
IBM International Business Machines	Target Set by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Ives Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$329.72 +2.9%	$350.00
IBRX ImmunityBio	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andres Y. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.23 -0.1%	$15.00	Buy
IDYA IDEAYA Biosciences	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Driscoll Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$27.87 -3.7%	$58.00	Outperform
IDYA IDEAYA Biosciences	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$27.87 -3.7%		Market Outperform
IEX IDEX	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bryan Blair Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$212.17 +2.2%	$242.00 ➝ $250.00	Outperform
INCY Incyte	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$92.24 -3.5%		Market Perform
INR Infinity Natural Resources	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Diamond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.29 +0.2%	$25.00 ➝ $20.00	Buy
INTU Intuit	Downgraded by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kash Rangan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$322.14 -8.9%	$519.00 ➝ $276.00	Neutral ➝ Sell
INTU Intuit	Target Lowered by	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$322.14 -8.9%	$700.00 ➝ $600.00	Buy
ISRG Intuitive Surgical	Target Lowered by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$402.30 -2.4%	$440.00 ➝ $366.00	Sell
ISRG Intuitive Surgical	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$402.30 -2.4%	$580.00	Overweight
JBIO Jade Biosciences	Target Set by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$17.75 -4.5%	$55.00
JBIO Jade Biosciences	Reiterated by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.75 -4.5%	$47.00	Buy
JBIO Jade Biosciences	Target Raised by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.75 -4.5%	$34.00 ➝ $45.00	Outperform
JCI Johnson Controls International	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$142.06 +6.1%	$169.00 ➝ $178.00	Buy
JCI Johnson Controls International	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Deane Dray Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$142.06 +6.1%	$154.00	Sector Perform
JCI Johnson Controls International	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Amit Mehrotra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$142.06 +6.1%	$170.00 ➝ $180.00	Buy
JCI Johnson Controls International	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$142.06 +6.1%		Market Perform
JUP Jupiter Fund Management	Target Raised by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 160.78	GBX 180 ➝ GBX 190	Hold
KNX Knight-Swift Transportation	Upgraded by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$77.63 -0.4%	$90.00	Neutral ➝ Positive
KRMN Karman	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$54.63 +1.8%	$100.00	Outperform
LIN Linde	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Spector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$495.91 -0.3%	$600.00	Buy
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
LINE Lineage	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ronald Kamdem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.98 -2.4%	$39.00 ➝ $47.00	Equal Weight
LNG Cheniere Energy	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$236.46 +3.8%	$300.00	Outperform
LTH Life Time Group	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Logan Reich Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$32.18 +2.7%	$38.00 ➝ $43.00	Outperform
MAC Macerich	Upgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Omotayo Okusanya Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.32 0.0%	$20.00 ➝ $27.00	Hold ➝ Buy
MAL Magellan Aerospace	Target Raised by	ATB Cormark Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$31.81	C$31.00 ➝ C$46.00	Outperform
MANE Veradermics	Initiated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Serge Belanger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$98.48 -3.0%	$136.00	Buy
MCHP Microchip Technology	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pradeep Ramani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$96.96 +5.9%		Buy
MDA MDA Space	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Konrad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.30 -0.4%	$51.00	Buy
MDB MongoDB	Target Raised by	Tigress Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ivan Feinseth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$398.46 -1.3%	$430.00 ➝ $515.00	Buy
MDB MongoDB	Reiterated by	Tigress Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$398.46 -1.3%		Buy
MELI MercadoLibre	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marvin Fong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,672.83 -3.4%	$2,150.00	Buy
META Meta Platforms	Target Set by	Arete Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rocco Strauss Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$597.63 -0.5%	$735.00	Neutral ➝ Buy
META Meta Platforms	Downgraded by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Buy ➝ Sell
META Meta Platforms	Upgraded by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Positive
META Meta Platforms	Initiated by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Outperform
META Meta Platforms	Upgraded by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Underperform ➝ Outperform
META Meta Platforms	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Ju Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$597.63 -0.5%		Buy ➝ Neutral
META Meta Platforms	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Champion Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$597.63 -0.5%		Overweight
META Meta Platforms	Initiated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Hold ➝ Buy
META Meta Platforms	Upgraded by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Outperform ➝ Neutral
MGM MGM Resorts International	Target Raised by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$48.29 -4.7%	$48.00 ➝ $55.00	Buy
MIRM Mirum Pharmaceuticals	Initiated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$92.17 -4.3%	$145.00	Market Outperform ➝ Buy
MKC McCormick & Company, Incorporated	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$46.28 -0.6%	$53.00 ➝ $51.00	Neutral
MLM Martin Marietta Materials	Target Set by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$578.65 +1.3%	$556.00	Hold
MNPR Monopar Therapeutics	Target Set by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$61.26 -4.9%	$105.00
MNPR Monopar Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$61.26 -4.9%		Buy
MOBI Mobia Medical	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.78 +2.1%	$31.00	Buy
MOBI Mobia Medical	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$13.78 +2.1%		Outperform
MOBI Mobia Medical	Initiated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.78 +2.1%	$16.00	Buy
MOBI Mobia Medical	Initiated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.78 +2.1%	$19.00	Buy
MOBI Mobia Medical	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.78 +2.1%	$15.00	Overweight
MRVL Marvell Technology	Target Set by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tore Svanberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$290.79 +32.5%	$321.00
MSGS Madison Square Garden	Target Set by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Curry Baker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$382.24 +1.2%	$470.00
MSM MSC Industrial Direct	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Newman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$115.04 +2.8%	$117.00 ➝ $120.00	Overweight
MSTR Strategy	Reiterated by	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$136.08 -9.1%		Neutral
MSTR Strategy	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Palmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$136.08 -9.1%		Buy
MTD Mettler-Toledo International	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,170.40 -1.1%		Peer Perform
MTRN Materion	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samuel McKinney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.88 +3.1%	$223.00 ➝ $237.00	Overweight
NAVN Navan	Target Raised by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Levine Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.87 +0.4%	$19.00 ➝ $28.00	Buy
NBIS Nebius Group	Initiated by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stefan Slowinski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$260.58 -1.5%	$255.00	Neutral
NBIX Neurocrine Biosciences	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Corinne Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$154.84 -3.8%	$213.00	Buy
NBPE NB Private Equity Partners	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 1,464		Buy
NHYDY Norsk Hydro ASA	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$13.02 +4.3%		Hold
NOAH Noah	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Zhang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$10.62 -0.3%	$12.00 ➝ $11.50	Neutral
NRR NewRiver REIT	Reiterated by	Shore Capital Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 76.70		House Stock
NRR NewRiver REIT	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 76.70	GBX 98 ➝ GBX 98	Buy
NTAP NetApp	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$175.64 -2.3%	$200.00	Buy
NTRA Natera	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$213.05 -2.6%	$260.00	Outperform
NU NU	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mario Pierry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$11.89 -8.4%	$16.00 ➝ $10.00	Neutral ➝ Underperform
NUTX Nutex Health	Initiated by	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Haynor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$125.03 -2.3%	$235.00	Buy
One page of the SpaceX S-1 will move this stock overnight (Ad) When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown. See the stock the S-1 revealed >>
NUVL Nuvalent	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$91.35 -1.8%		Overweight
NVDA NVIDIA	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Quinn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$222.82 -0.7%	$270.00	Buy
NVDA NVIDIA	Reiterated by	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$222.82 -0.7%		Outperform
OBE Obsidian Energy	Reiterated by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$12.33 +6.5%		Outperform
OBE Obsidian Energy	Target Raised by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$16.00	C$19.00 ➝ C$20.00	Outperform
ODD ODDITY Tech	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan MacDonald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.84 -29.6%		Hold
ODFL Old Dominion Freight Line	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$229.08 +0.2%	$205.00 ➝ $224.00	Neutral
ODTX Odyssey Therapeutics	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Jones Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.93 -0.2%	$40.00	Outperform
ODTX Odyssey Therapeutics	Initiated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.93 -0.2%	$30.00	Outperform
ODTX Odyssey Therapeutics	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Cheng Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.93 -0.2%	$26.00	Overweight
ODTX Odyssey Therapeutics	Initiated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Van Buren Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.93 -0.2%		Buy
ODTX Odyssey Therapeutics	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.93 -0.2%		Overweight
OKTA Okta	Reiterated by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregg Moskowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$135.32 -3.2%	$110.00 ➝ $125.00	Outperform ➝ Neutral
ONC BeOne Medicines	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$274.69 -1.8%	$425.00 ➝ $436.00	Outperform
OPTU Optimum Communications	Upgraded by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1.18 +1.3%		Underperform ➝ Neutral
ORCL Oracle	Target Raised by	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Colville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$244.80 -1.4%	$215.00 ➝ $290.00	Sector Outperform
ORCL Oracle	Reiterated by	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pat Colville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$244.80 -1.4%		Outperform
ORCL Oracle	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Karl Keirstead Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$244.80 -1.4%	$250.00 ➝ $285.00	Buy
ORKA Oruka Therapeutics	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$55.23 +0.4%	$180.00	Overweight
OXB Oxford Biomedica	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 616	GBX 8.27 ➝ GBX 8.27	Buy
OXM Oxford Industries	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mauricio Serna Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$45.97 +2.9%	$33.00 ➝ $42.00	Neutral
PAG Paragon Banking Group	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 737.50	GBX 1,000 ➝ GBX 1,000	Buy
PENG Penguin Solutions	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Chin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$70.65 +18.3%	$24.00 ➝ $66.00	Buy
PENG Penguin Solutions	Target Raised by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Cassidy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$70.65 +18.3%	$54.00 ➝ $65.00	Buy
PGNY Progyny	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.12 -4.1%	$29.00 ➝ $31.00	Buy
PRAX Praxis Precision Medicines	Target Lowered by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$166.00 ➝ $162.00	Underperform
PRAX Praxis Precision Medicines	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$1,245.00 ➝ $1,201.00	Buy
PRAX Praxis Precision Medicines	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$433.00 ➝ $400.00	Outperform
PRAX Praxis Precision Medicines	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$750.00 ➝ $650.00	Outperform
PRAX Praxis Precision Medicines	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$258.08 -23.0%		Buy
PRAX Praxis Precision Medicines	Target Set by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$715.00 ➝ $616.00	Buy
PRAX Praxis Precision Medicines	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Hoang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$420.00 ➝ $374.00	Buy
PRAX Praxis Precision Medicines	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kambiz Yazdi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.08 -23.0%	$843.00 ➝ $810.00	Buy
QBTS D-Wave Quantum	Target Raised by	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suji Desilva Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.97 +2.7%	$30.00 ➝ $40.00	Buy
QBTS D-Wave Quantum	Target Raised by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Ellis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.97 +2.7%	$36.00 ➝ $40.00	Buy
QBTS D-Wave Quantum	Target Set by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ruben Roy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.97 +2.7%	$35.00
QBTS D-Wave Quantum	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Quinn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.97 +2.7%	$40.00	Buy
QBTS D-Wave Quantum	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John McPeake Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.97 +2.7%	$43.00	Buy
RACE Ferrari	Reiterated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$353.64 +1.3%		Outperform
RAPP Rapport Therapeutics	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$34.90 -6.0%		Market Outperform
RGEN Repligen	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$121.13 -1.6%	$145.00	Outperform
RIGL Rigel Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.02 +0.5%	$57.00	Buy
RIO Rio Tinto Group	Target Lowered by	Shore Capital Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 8,051	GBX 7,400 ➝ GBX 6,900	Hold
ROSE Rose Petroleum plc (ROSE.L)	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 345	GBX 4.70 ➝ GBX 4.70	Buy
ROSE Rose Petroleum plc (ROSE.L)	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 345	GBX 4,500 ➝ GBX 4,500	Buy
RPD Rapid7	Target Raised by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rudy Kessinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.43 -3.5%	$5.25 ➝ $6.50	Underperform
RPD Rapid7	Upgraded by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Meta Marshall Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.43 -3.5%		Outperform ➝ Neutral
RVMD Revolution Medicines	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$151.31 -7.6%	$165.00 ➝ $182.00	Outperform
RVTY Revvity	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$100.28 -0.2%		Peer Perform
RZLT Rezolute	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.00 +10.8%	$5.00	Buy
RZLT Rezolute	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$4.00 +10.8%		Buy
SAIA Saia	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$471.15 -2.3%	$425.00 ➝ $465.00	Neutral
SAIC Science Applications International	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Godyn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$113.36 -1.5%	$120.00 ➝ $132.00	Buy
SAIC Science Applications International	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seth Seifman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$113.36 -1.5%	$110.00 ➝ $125.00	Neutral
SAIC Science Applications International	Reiterated by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tobey Sommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$113.36 -1.5%	$95.00 ➝ $110.00	Hold
SAIL SailPoint	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Saket Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.84 +3.1%	$16.00 ➝ $22.00	Overweight
SARO StandardAero	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sheila Kahyaoglu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.17 -8.0%	$34.00 ➝ $30.00	Buy ➝ Hold
SDI SDI Group	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 82.60	GBX 145 ➝ GBX 145	Buy
SEPL Seplat Energy	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 573	GBX 6,550 ➝ GBX 6,650	Buy
SEZL Sezzle	Reiterated by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Hal Goetsch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$118.43 -3.4%	$117.00 ➝ $141.00	Buy
SFTBY SoftBank Group	Downgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$27.38 -4.5%		Buy ➝ Hold
SGBAF SES	Downgraded by	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$10.35 -3.7%		Neutral ➝ Sell
SGY Surge Energy	Target Raised by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$10.02	C$12.00 ➝ C$13.00	Outperform
SGY Surge Energy	Target Raised by	Acumen Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$10.02	C$13.25 ➝ C$13.75	Buy
SGY Surge Energy	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$10.02	C$12.00 ➝ C$13.00	Buy
SGY Surge Energy	Target Raised by	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$10.02	C$12.75 ➝ C$13.50	Outperform
SGY Surge Energy	Target Raised by	ATB Cormark Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$10.02	C$12.00 ➝ C$13.00	Outperform
SHAK Shake Shack	Target Set by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Tamas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.95 -8.5%	$82.00	Outperform
SHAK Shake Shack	Target Set by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Curtis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$56.95 -8.5%	$70.00
SHAK Shake Shack	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$56.95 -8.5%	$66.00	Hold
SHW Sherwin-Williams	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Spector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$292.65 -0.8%	$385.00 ➝ $330.00	Buy ➝ Neutral
SJM J. M. Smucker	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$100.34 -0.3%	$132.00 ➝ $121.00	Buy
SMG Scotts Miracle-Gro	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$56.47 -3.9%	$63.00	Neutral
SMPL Simply Good Foods	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$11.81 +1.3%	$13.00 ➝ $12.00	Neutral
SNDR Schneider National	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$36.44 +0.2%	$34.00 ➝ $36.00	Neutral
SOC Sable Offshore	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$13.59 +4.3%		Hold
SQM Sociedad Quimica y Minera	Upgraded by	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$80.71 -3.2%		Outperform
SQM Sociedad Quimica y Minera	Target Set by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$80.71 -3.2%	$100.00
SQM Sociedad Quimica y Minera	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lucas Ferreira Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$80.71 -3.2%	$94.00 ➝ $100.00	Overweight ➝ Neutral
SQZ Serica Energy	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 259.80	GBX 350 ➝ GBX 350	Buy
SQZ Serica Energy	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 259.80	GBX 310 ➝ GBX 310	Buy
SRE Sirius Real Estate	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 98.55	GBX 120 ➝ GBX 120	Buy
ST Sensata Technologies	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kosta Tasoulis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$53.21 +8.0%	$42.00 ➝ $48.00	Equal Weight
ST Sensata Technologies	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Snyder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$53.21 +8.0%	$57.00	Buy
STB Secure Trust Bank	Reiterated by	Shore Capital Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 1,284		House Stock
STM STMicroelectronics	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Didier Scemama Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$79.61 +15.3%	$73.00 ➝ $83.00	Neutral
STRL Sterling Infrastructure	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sangita Jain Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$875.52 +3.6%	$889.00 ➝ $922.00	Overweight
STVN Stevanato Group	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	€18.92 +0.3%	$21.00	Outperform
STWD Starwood Property Trust	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marissa Lobo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.09 +1.7%	$19.50 ➝ $20.00	Neutral ➝ Buy
STX Seagate Technology	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asiya Merchant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$926.61 +0.6%	$740.00 ➝ $1,150.00	Buy
TEM Tempus AI	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$49.62 -6.0%		Peer Perform
TFII TFI International	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$158.90 +1.7%	$134.00 ➝ $182.00	Positive
TMC TMC the metals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Heiko F. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$6.49 +2.0%	$11.75	Buy
TMHC Taylor Morrison Home	Downgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Dahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$71.51 -0.1%	$69.00 ➝ $72.50	Outperform ➝ Sector Perform
TMO Thermo Fisher Scientific	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$480.62 -2.7%	$535.00	Outperform
TOL Toll Brothers	Target Set by	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$139.40 +0.7%	$170.00
TPR Tapestry	Reiterated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$138.64 -0.1%	$180.00	Outperform
TRIP TripAdvisor	Initiated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Piccolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$11.94 -1.3%	$19.00	Neutral ➝ Outperform
TTWO Take-Two Interactive Software	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Callahan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$222.38 -2.0%	$280.00	Overweight
TVTX Travere Therapeutics	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.94 -4.7%	$57.00 ➝ $67.00	Buy
U Unity Software	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Callahan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.85 -4.1%	$35.00 ➝ $40.00	Overweight
UCU Ucore Rare Metals	Target Lowered by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$6.11 +7.0%	C$15.00 ➝ C$14.75	Outperform
UMAC Unusual Machines	Target Raised by	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Irwin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$33.42 +15.7%	$40.00	Buy
UNCY Unicycive Therapeutics	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.23 -4.9%	$15.00 ➝ $18.00	Speculative Buy
V Visa	Reiterated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$317.36 -1.7%	$450.00	Outperform
VC Visteon	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Langan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$123.90 +4.9%	$125.00 ➝ $139.00	Overweight
VCTR Victory Capital	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$85.06 +0.5%	$90.00	Neutral
VCYT Veracyte	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$47.80 -0.8%	$55.00	Outperform
VERA Vera Therapeutics	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$31.26 -7.9%		Buy
VERA Vera Therapeutics	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$31.26 -7.9%	$90.00	Buy
VMC Vulcan Materials	Target Set by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$282.06 +0.2%	$283.00	Hold
VNP 5N Plus	Target Raised by	Desjardins Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$41.00	C$43.00 ➝ C$50.00	Buy
VNRX VolitionRX	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2.32 -12.5%		Hold
VRRM Verra Mobility	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Koning Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.16 -14.9%	$8.00 ➝ $6.00	Neutral
VVX V2X	Reiterated by	Noble Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$83.10 -0.7%		Outperform
WALD Waldencast	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Susan Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.85 +1.1%	$2.00 ➝ $3.00	Buy
WAT Waters	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derik De Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$371.90 -1.7%	$370.00 ➝ $400.00	Neutral
WAT Waters	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$371.90 -1.7%	$425.00	Outperform
WDC Western Digital	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asiya Merchant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$563.10 +3.1%	$500.00 ➝ $685.00	Buy
WERN Werner Enterprises	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.99 +1.1%	$38.00 ➝ $47.00	Neutral
WISE Wise	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 858	GBX 1,299 ➝ GBX 1,299	Buy
WS Worthington Steel	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samuel McKinney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$43.91 +2.9%	$38.00 ➝ $46.00	Overweight
WST West Pharmaceutical Services	Reiterated by	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Etoch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$312.77 -1.1%	$360.00	Overweight
WT WisdomTree	Target Set by	Northland Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Grondahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.96 -1.0%	$22.00
XFOR X4 Pharmaceuticals	Initiated by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.04 -1.7%	$12.00	Outperform
XPO XPO	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$216.67 -2.1%	$210.00 ➝ $212.00	Neutral
ZM Zoom Communications	Target Raised by	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Bersey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$111.88 +0.2%	$107.00 ➝ $133.00	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:47 PM ET.

Stock Ratings and Recommendations: Understanding Analyst Ratings

Written by MarketBeat Staff

Key Points

Stock analysts give ratings to companies based on their research and insights.
Analysis comes from the buy side (fund companies, investment managers) or sell side (brokers, banks).
Analysts use different methodologies, so investors should always look into why a particular rating was given.
5 stocks we like better than EXA)

You'll often hear a particular stock called a "buy" or "sell," but who exactly makes these calls? Ratings and recommendations come from stock analysts, who research different securities and work for various institutions, brokerage firms and other financial companies.

Analyst ratings are designed to give additional information to investors beyond just what the company is saying, but are analyst ratings reliable? In this article, we'll discuss how to read analyst ratings, what goes into their decision-making process and how potential conflicts of interest influence analyst stock ratings.

What Are Analyst Ratings?

A stock rating is a simple heuristic given by analysts who review the firm's financial statements, listen to conference calls, chat with company executives and compare the stock to others in the industry or sector. Finally, an analyst uses all this information to produce a simple recommendation and price target.

When a public analyst goes on CNBC or the "Wall Street Journal" to give a "buy" or "sell" rating on a particular stock, they take all their research and pare it down into a simple designation. While there's no true consensus on what constitutes a buy or sell rating, an analyst usually does have "skin in the game" when devising ratings.

Ratings often pair with price targets, which put a hard number on what the analysts believe the company stock should be worth. So, for example, you might see an analyst report something like, "Buy NVIDIA Inc. (NASDAQ: NVDA), price target $350," which means that particular analyst believes investors should buy NVDA shares up to a price of $350 per share.

Analyst ratings infographic: What you need to know

What Does a Stock Analyst Do?

A stock analyst is a market professional with the skills to interpret financial data and the connections within companies to speak on the record with higher-ups. Analysts generally fall into one of two different camps: buy-side or sell-side. These positions will seem similar, but they tend to be employed by various institutions and have different responsibilities in their particular market "territories."

Buy-side analysts: Analysts on the buy side tend to work for funds, such as ETF providers or hedge funds. They don't dig as deeply into company financial data or conference calls as sell-siders. Instead, they focus on general areas or industries where their funds have vested interests. In addition, buy-side analysts often forge relationships with sell-side analysts for individual stock research. A buy-side analyst's primary goal is to find and utilize the most accurate and dependable sell-side analysts.
Sell-side analysts: If buy-side analysts work for funds (i.e., institutions that buy securities), you can probably guess which type of institution employs sell-side analysts. Brokers, banks and other firms that sell securities to investors use sell-side analysts to give reports to the public. While buy-side analysts also give ratings and price targets, the reported "buy" and "sell" ratings in financial media typically come from folks on the sell side.

Buy and sell-side analysts often use different rating systems when making their recommendations. You might even find two sell-side analysts with similar "buy" recommendations with vastly different price targets in the same stock. As a result, you'll need to familiarize yourself with the various methodologies analysts use to utilize their research correctly.

What Ratings Do Analysts Give?

Stock analyst ratings don't follow a strict structure, although most have roughly the same grading system for the securities they review. The labels may differ slightly (i.e., overweight vs. outperform), but the five most common analyst ratings go like this.

Buy

Analysts bullish on a particular security will give it a "buy" rating and set a price target above the current market price. In addition, if the analyst considers the stock one of the best in the industry or sector, you'll sometimes see a "strong buy" rating attached.

Hold

A "hold" rating is typically the lowest rating a sell-side analyst gives a stock. "Hold" means the analyst projects the stock to meet the return of the market averages, making it an unspectacular investment. Stocks rated "hold" may still have a price target above the current price, but it's not likely to surpass the return of a major index like the S&P 500.

Sell

Analysts are usually apprehensive about giving a stock a "sell" rating. For example, suppose a "hold" rating indicates indecision over the stock's future. In this scenario, a "sell" rating is issued when an analyst finds something unappealing, such as questionable accounting tactics or cratering sales growth.

Underperform

Analysts won't always give a firm "buy" or "sell" rating on stock but will instead label it "underperform" or "outperform." "Underperform" means the analyst expects the stock not to keep up with the market. It doesn't necessarily mean the analyst predicts a crash but indicates a lack of confidence in the shares.

Outperform

"Outperform" is the opposite of "underperform," meaning the analyst expects the stock to do better than the market average. It's usually considered a less confident rating than "buy."

Example of an Analyst Rating

You can use MarketBeat Analyst Ratings to find ranges and aggregates from buy- and sell-side analysts across the financial media. For example, here's a stock that analysts usually love: Alphabet Inc. (NASDAQ: GOOG).

Overview of stock analysis on GOOG Using MarketBeat's tools, you can find ratings from prominent analysts from multiple periods. Alphabet is currently labeled a "moderate buy" based on MarketBeat's consensus from 17 analysts. You'll get the consensus price target and the highest and lowest from the analysts surveyed.

Marketbeat's tools detailing analyst ratings

Looking at analyst recommendations over time is another helpful tool. For example, you can view the different levels of coverage over the last few years, which analysts changed their ratings and how the price targets vary from month to month. If an analyst can't get a good read on a particular stock they've been covering, they might choose to withhold their grade, which is one reason why the number of available ratings can change over time.

Overview of analyst ratings on MarketBeat Analysts from both sides of the aisle can be found on MarketBeat, ranging from large firms like JPMorgan Chase and Co. (NYSE: JPM) to smaller investment banks like Roth Capital. Some institutions like UBS Group offer both buy-side and sell-side ratings and analysis. These graphs show that even analysts with similar ratings can have vastly different price targets, so always understand the reasoning behind an analyst's view.

How to Use Analyst Ratings

Here are a few pointers on incorporating analyst ratings into your investment research.

Step 1: Don't rely on a single analyst.

Using an array of analysts (buy- and sell-side) gives inventors the most possible information. Don't just look for analysts with similar opinions as yourself — ensure you understand the pros and cons of each investment you make by incorporating positive and negative views, if possible.

Step 2: Compare analyst ratings across the industry or sector.

It's easy to slap a "buy" rating on a stock and predict a winner, but comparing stocks against others in the sector can offer insight into the rating. For example, if a stock is rated "buy" in the information technology sector, but a dozen others are rated "strong buy" by the same analyst, where is your capital best served?

Step 3: Consider your own goals and risk tolerance.

You might find stocks rated "strong buy" in your research in sectors you wish to avoid. That's fine! There are thousands of securities across dozens of industries in the public markets, and you don't need to purchase every share that comes with a "buy" rating. Instead, stick to your investment plan.

Step 4: Don't stubbornly stick to your original assessments.

Following your investment plan and using analyst ratings as guidelines are practical steps, but things can change over time. Today's "strong buy" stocks could be "strong sell" stocks down the road. Using an aggregate of analysts' ratings can help investors view stocks from a higher level. For example, if the number of "buy" ratings on a stock drops 40% over a few years, you might want to take a closer look at that particular company.

Why Are Analyst Ratings Important?

Checking out analyst ratings isn't a necessary step for investing, but it can be helpful for those looking to dig deep into an asset's prospects. Analyst research often has quotes from company executives, questions from conference calls and in-depth reporting on the company's balance sheet, income statement and other essential documents. Analysis like this is complex for individual investors to do on their own, especially considering how frequently analysts interact with the executives they cover. But access often comes with a downside, which we discuss more below.

How Accurate Are Analyst Ratings?

Both buy and sell-side analysts strive for accuracy because giving consistently wrong commendations can be hazardous for job security. However, investors should be aware that analysts might not always have the best interest of the retail investor at heart when making their recommendations.

For starters, being an analyst requires access to company employees and management. Analysts typically ask questions during conference calls and speak with C-suite executives on the record about their firms' prospects. Executives usually don't want to hear adverse reports about their companies, so analysts are incentivized to paint a rosy picture to retain access. The SEC has been questioning the authenticity of analyst ratings (especially on the sell-side) since 2002 when it asked bluntly, "Why are there so few sell ratings?"

Of course, there are other areas of the securities analysis market to face scrutiny. If you recall, during the 2008 financial crisis, the biggest credit rating agencies were all held to the fire due to claims that conflicts of interest influenced their ratings. The biggest rating agencies in the world were accused of "misrepresenting the risks associated with mortgage-backed securities." Remember, analyst ratings aren't spat out by computer algorithms but by living, breathing people who may have agendas other than providing the most precise and accurate reports on a company's future prospects.

Analyst Ratings Can Guide Investors, but Don't Treat Them as Gospel

Consider each type of investment research or advice in collaboration. Even the most accurate and thoughtful analysts get things wrong, plus ratings are frequently besieged with conflicts of interest. But analyst coverage does offer research that's difficult to get elsewhere, and using an array of analyst reports can give investors a deeper understanding of the securities they buy.

FAQs

Still have questions about analyst ratings? Here are a few answers to some common points of discussion:

What are analyst ratings?

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Should you trust analyst ratings?

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

What does an analyst rating tell you about a stock?

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stock Price Targets and Analyst Ratings